Just did some research on biotech ETF options and wanted to share what I found. If you're looking to get exposure to the biotech sector without picking individual stocks, ETFs are definitely the safer play given how unpredictable biotech can be.

I looked at the major players from late 2024 data. The biggest by assets was XBI (SPDR S&P Biotech ETF) sitting at around 7.82 billion, followed closely by IBB (iShares NASDAQ Biotech ETF) at 7.33 billion. Both are solid for broad exposure - XBI leans more toward smaller cap biotech companies with 144 holdings, while IBB casts a wider net with 211 holdings including pharma and life sciences tools.

If you want something more focused on next-gen stuff like CRISPR and genomics, ARK's ARKG is the move, though it's smaller at 1.31 billion in assets. Then there's FBT (First Trust NYSE Arca Biotech) with only 31 holdings, which means each position gets more weight. And if you're feeling aggressive, LABU is the 3x leveraged biotech ETF - definitely not for the faint of heart.

The appeal of going the biotech ETF route is you're not betting on one company's drug trial or FDA approval. You're spreading risk across multiple companies in the space. Worth considering if you want biotech exposure but don't want to stress over individual stock picks.